Optimal compositions and methods thereof for treating HCV infections
US6824769B2 · kind B2 · utility
20Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2001 |
| Grant date | Nov 30, 2004 |
| Priority date | — |
| Expiry date | Aug 28, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein:Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; andCmin is estimated trough concentration produced by said IMPDH inhibitor in said human.The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.